泰励生物用于治疗靶向疗法耐药性的多激酶抑制剂TSN084获得美国FDA临床试验许可

上海，2021年10月17日 – 泰励生物，一家聚焦于探索耐药性肿瘤创新疗法的生物技术公司，宣布美国食品药品监督管理局 (FDA) 已批准其小分子新药TSN084的IND申请，用于治疗实体肿瘤。TSN084是拥有自主知识产权的全球首创的多激酶抑制剂，靶向CDK8/19及其他几种与肿瘤增殖和免疫逃逸密切相关的激酶。这项临床研究即将在美国M.D. 安德森癌症中心开展。

泰励生物用于治疗靶向疗法耐药性的多激酶抑制剂TSN084获得美国FDA临床试验许可

张彦涛博士

泰励生物联合创始人兼首席执行官张彦涛 (Tony Zhang)博士评论说：

“TSN084是泰励创新管线产品中的领跑者，具有非常特异的靶点组合。临床前研究已充分展现出这个药物针对数个与肿瘤耐药进展相关的激酶靶点同时立体进攻的有效性和良好的耐受性。FDA 的临床许可批准使我们朝着实现为难治肿瘤如三阴性乳腺癌患者提供更有效更安全更可及的治疗方案的目标又迈进了一步。”

关于泰励生物科技（上海）有限公司

泰励生物（Tyligand Bioscience）是一家聚焦于耐药性肿瘤药物研发的临床阶段生物技术公司。我们基于对于生物分子磷酸化水平及其信号传导通路的深入理解，致力于打造一条高度差异化的全球创新研发管线，包含全球首个双功能免疫激动剂平台（DATIA®）及抗体偶联药物ADC的创新载荷平台。

如有需进一步了解，请邮件：BD@tyligand.com

Tyligand Bioscience receives IND clearance from U.S. FDA for TSN084, a Multi-kinase Inhibitor to address tumor resistance to targeted therapies

Shanghai, Oct. 17th, 2021 – Tyligand Bioscience, a clinical-stage biotechnology company focused on developing innovative therapies against drug resistant cancers, announces that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application to commence a Phase I clinical trial investigating the safety and efficacy of TSN084 for treating solid tumors. TSN084 is a novel multi-kinase inhibitor targeting CDK8/19 and several other kinases implicated in tumorigenesis and immune evasions. The clinical study is scheduled to start at the M.D Anderson Cancer Center in the US soon.

Dr. Tony Zhang, cofounder and CEO of Tyligand Bioscience, commented:

“TSN084 is the front runner of the Tyligand pipeline of innovative molecules designed to treat tumors that become resistant to targeted therapies. It has demonstrated potent activities against a unique combination of kinase targets responsible for several major cancer hallmarks in preclinical studies. FDA’s decision has moved us one step closer towards translating these findings into clinical outcomes for patients suffering from NSCLC, TNBC and other hard to treat cancers.”

About Tyligand Bioscience (Shanghai) Limited

Tyligand Bioscience is a clinical stage biotechnology company focused on the discovery and development of cancer therapeutics to address drug resistant tumors like NSCLC and TNBC. Leveraging deep insights into the chemistry of biomolecule phosphorylation, the company has efficiently built a differentiated pipeline including 1st-in-class Dual Action Tumor Immune Agonist (DATIA®) assets and a novel platform for ADC payload discovery and development.